Publication

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack, S
; 
Smeland, S
; 
Whelan, J
; 
Marina, N
; 
Jovic, G
; 
Hook, J
; 
Krailo, M
; 
Gebhardt, M
; 
Pápai, Z
; 
Meyer, J
... show 10 more
Citations
Altmetric:
Abstract
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.
Authors
Bielack, S
Smeland, S
Whelan, J
Marina, N
Jovic, G
Hook, J
Krailo, M
Gebhardt, M
Pápai, Z
Meyer, J
Nadel, H
Randall, R
Deffenbaugh, C
Nagarajan, R
Brennan, Bernadette M
Letson, G
Teot, L
Goorin, A
Baumhoer, D
Kager, L
Werner, M
Lau, C
Sundby Hall, K
Gelderblom, H
Meyers, P
Gorlick, R
Windhager, R
Helmke, K
Eriksson, M
Hoogerbrugge, P
Schomberg, P
Tunn, P
Kühne, T
Jürgens, H
van den Berg, H
Böhling, T
Picton, S
Renard, M
Reichardt, P
Gerss, J
Butterfass-Bahloul, T
Morris, C
Hogendoorn, P
Seddon, B
Calaminus, G
Michelagnoli, M
Dhooge, C
Sydes, M
Bernstein, M
Affiliation
Klinikum Stuttgart-Olgahospital, Stuttgart
Description
Date
2015-06-01
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. 2015: J Clin Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/559317
Embedded videos